TCTMD - tctmd.com
CME. There is a growing recognition of the prevalence and outcomes associated with tricuspid regurgitation, whether in isolation or with concomitant diseases. This program will focus on defining the burden of disease, outlining current guideline directed medical therapy and discussing the recent evidence for transcatheter therapies.
TCTMD Login - tctmd.com
TCTMD Login - tctmd.com. Email Address. Password. Advertisement. Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors ...
Injectable Semaglutide Shortage Forces Physicians to Pivot
Feb 5, 2024 · And across the Atlantic, the European Medicines Agency has also put out a notice on a shortage of injectable semaglutide—specifically the Ozempic prefilled pens at doses of 0.25, 0.5, and 1 mg—due to both burgeoning demand and manufacturing issues. The agency said the shortfall is expected to continue through this year.
Slides | tctmd.com
Apr 14, 2024 · SCCT 2023. Boston, MA. July 27. July 30, 2023. See All Conferences. The best online resource for cardiology conference slides around the globe.
Cheaper Version of Tirzepatide for Weight Loss Now Available, …
Aug 28, 2024 · The manufacturer is selling single-dose vials of the drug via its online pharmacy at around $400 to $500 for a 4-week supply. Tirzepatide, when used for weight loss under the brand name Zepbound, is now more affordable thanks to a …
Micra Leadless Pacemaker Performs Well Through 5 Years
Mar 6, 2024 · The Micra VR leadless pacemaker (Medtronic) continues to have a good safety and efficacy profile through the 5-year mark, according to real-world registry data. Rates of major complications and revisions were both under 5%, and no patients required device removal for infection. Moreover, as researchers led by Mikhael El-Chami, MD (Emory ...
When the Time Comes to Stop Oral Anticoagulation: Options and …
Sep 28, 2021 · Published in 2019, the analysis estimates the net clinical benefit of oral anticoagulation beyond age 75 in patients with AF, showing that the benefits become marginal after age 87 for warfarin and after age 92 for apixaban (Eliquis; Bristol-Myers Squibb). It shows “that we really need personalized and individualized decision-making where if ...
FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels
Dec 22, 2021 · The US Food and Drug Administration has approved inclisiran (Leqvio; Novartis), a small interfering RNA (siRNA) therapy, for lowering LDL cholesterol levels, the drugmaker announced today. The treatment is approved as an adjunct to diet and maximally tolerated statin therapy in patients with atherosclerotic cardiovascular disease (ASCVD) or ...
TCT 2023 - TCTMD.com
Oct 23, 2023 · TCT 378: A novel miRNA nanocarrier for local device-based pharmacotherapy. October 26, 2023. Presentation TCT 2023.
‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry
Jan 10, 2020 · With a list price of $225,000 per year, tafamidis is the most expensive cardiovascular drug on the market. Mathew Maurer, MD (Columbia University Irving Medical Center, New York, NY), who published his views along with Jerry Gurwitz, MD (University of Massachusetts Medical School, Worcester), January 8, 2020, in …